Development of highly antibiotic resistant strains of infections such as staphylococcus and tuberculosis warrant the search for new antibacterial chemotherapies. With vanishing antibiotic therapies available for such infections and with little pharmaceutical company input into such problems, it is critical for many researchers to investigate novel therapies against these bacterial threats. The projects that we are working on involve the synthesis of isoxazoline and thiolactone compounds, which have shown potential for antibacterial activity. These heterocycles have interesting activity against numerous organisms that could prove useful, especially as we vary the substituents on the heterocycle to look for increases and decreases in activity against certain organisms. We have begun making compounds with the general isoxazoline moiety and a compound similar to Thiolactomycin. We are interested in the 1,3-dipolar addition reaction with questions to probe that reaction that include: What effect will changes in the substituents have on the resulting regiochemistry of the product? Can we control the regiochemistry? And can we build another antibiotic?